Mark Guerin
Annovis BioAbout Mark Guerin
Mark Guerin (age 57) was appointed Chief Financial Officer of Annovis Bio (ANVS) effective September 25, 2025. He holds a B.S. in Accounting from DeSales University and professional certifications as a CPA, CMA, and CFM. Prior to ANVS, he served as CFO of Onconova Therapeutics (now Traws Pharma, Nasdaq: TRAW), with a track record of executing multiple financing transactions and strengthening reporting, forecasting, and internal controls post-IPO. Given his recent appointment, ANVS has not disclosed TSR, revenue growth, or EBITDA performance metrics tied to his tenure to date .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Onconova Therapeutics / Traws Pharma (Nasdaq: TRAW) | Chief Financial Officer | 2016–Feb 2025 | Executed rights offering, public/registered direct/ATM offerings; supported merger with Trawsfynydd Therapeutics and subsequent financings . |
| Onconova Therapeutics | Senior finance leadership (post-IPO) | Joined 2013 | Augmented financial reporting, forecasting, and internal controls after July 2013 IPO . |
| Cardiokine, Inc. | VP Finance / CFO | Not disclosed | Oversaw NDA filing and subsequent company sale . |
| Barrier Therapeutics, Inc. | Director, Financial Reporting & Internal Controls | Not disclosed | Supported company through IPO and follow-on offering . |
| Private equity portfolio companies | Interim senior finance/accounting executive | Not disclosed | Led post-acquisition integration for newly acquired portfolio companies . |
| Coopers & Lybrand (Philadelphia) | Public accounting | Not disclosed | Early career audit/finance foundation . |
External Roles
- No public-company directorships or committee roles disclosed in ANVS filings reviewed .
Fixed Compensation
| Component | Terms |
|---|---|
| Base salary | $450,000 annually . |
| Target annual bonus | 40% of base salary . |
| Benefits | Eligible to participate in employee benefit plans generally available to ANVS employees . |
Performance Compensation
| Incentive type | Metric(s) | Weighting | Target | Actual/Payout | Vesting/Notes |
|---|---|---|---|---|---|
| Annual cash bonus | Not disclosed (company/individual criteria not specified for Guerin) | Not disclosed | Target 40% of base salary | Not disclosed | Determined under Company’s compensation framework; specific metrics not provided in 8-K . |
| Stock options | Equity value creation (service-linked; performance conditions not disclosed) | Not disclosed | 200,000 options | Grant disclosed; strike/expiration not disclosed | Vesting schedule not disclosed in 8-K . |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Initial equity grant | Stock options to purchase 200,000 ANVS shares . |
| Potential dilution context | 200,000 options represent ~1.0% of 20.2M shares outstanding as of 9/30/2025 (200,000 ÷ 20.2M) . |
| Strike price / expiration | Not disclosed in appointment 8-K . |
| Vesting schedule | Not disclosed in appointment 8-K . |
| Total beneficial ownership at appointment | Not disclosed; not included in 2025 proxy ownership table (as of 4/28/2025, prior to his appointment) . |
| Pledging/hedging | No pledging/hedging disclosures specific to Guerin identified in reviewed filings . |
| Clawback applicability | ANVS maintains an NYSE-compliant clawback policy covering current and former executive officers; recovery of excess incentive comp (cash and equity) tied to restatements within a 3-year lookback (effective for compensation on/after Oct 2, 2024) . |
Employment Terms
| Term | Detail |
|---|---|
| Start date / role | Appointed CFO effective September 25, 2025 . |
| Severance | Six months severance pay if employment is terminated (further detail not disclosed) . |
| Change-of-control | Not disclosed in appointment 8-K . |
| Non-compete / non-solicit | Not disclosed in appointment 8-K . |
| Certifications | As Principal Financial Officer, executed SOX 302 and 906 certifications with the Q3 2025 Form 10-Q . |
Investment Implications
- Alignment and dilution: A 200,000-share option grant aligns incentives with shareholders; if fully exercised, it equates to ~1% of shares outstanding as of 9/30/2025, a modest incremental dilution for a small-cap biotech .
- Cash vs. equity mix and retention: Fixed pay ($450k base, 40% target bonus) plus options suggests a balanced structure with meaningful at-risk equity to support retention and performance alignment; exact vesting terms were not disclosed, limiting visibility into near-term vest-related selling pressure .
- Governance and recourse: NYSE-compliant clawback covering executives (including equity) provides downside protection for shareholders in the event of a restatement, indicating a more shareholder-aligned incentive framework .
- Capital markets execution: Guerin’s prior record of executing multiple financing modalities (rights, public, registered direct, ATM) and M&A/NDA experience is additive for ANVS as it advances late-stage clinical programs and may require balance sheet flexibility .
- Disclosure gaps: Lack of disclosed vesting schedule, strike price, change-of-control terms, and ownership guidelines reduces ability to fully assess pay-for-performance sensitivity, retention risk, and potential insider selling catalysts at this time .